BRIEF published on 06/20/2025 at 07:05, 1 year ago Relief Therapeutics fait face à un revers de la FDA concernant la désignation QIDP du RLF-TD011 RLF-TD011 Médicament Orphelin Réponse De La FDA Epidermolyse Bulleuse Désignation QIDP
PRESS RELEASE published on 06/20/2025 at 07:00, 1 year ago Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 Relief Therapeutics receives FDA response on QIDP request for RLF-TD011, impacting EB treatment strategy with Orphan Drug and Rare Pediatric Disease designations Relief Therapeutics RLF-TD011 FDA Response Epidermolysis Bullosa QIDP Request
BRIEF published on 06/12/2025 at 11:05, 1 year ago Relief Therapeutics Announces Results of Annual General Meeting Financial Statements Shareholder Approval Annual Meeting Board Elections Compensation Approval
BRIEF published on 06/12/2025 at 11:05, 1 year ago Relief Therapeutics annonce les résultats de son assemblée générale annuelle États Financiers Réunion Annuelle Approbation Des Actionnaires Élections Du Conseil D'administration Approbation De L'indemnisation
PRESS RELEASE published on 06/12/2025 at 11:00, 1 year ago Relief Therapeutics Announces Results of Annual General Meeting Relief Therapeutics announces results of its Annual General Meeting with shareholders approving all proposals by a large majority. AGM covers key agenda items and re-election of board members and auditors Board Of Directors Annual General Meeting Shareholders Relief Therapeutics AGM Results
BRIEF published on 05/22/2025 at 07:05, 1 year 1 month ago Relief Therapeutics Secures FDA Rare Pediatric Disease Designation for RLF-TD011 FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease
BRIEF published on 05/22/2025 at 07:05, 1 year 1 month ago Relief Therapeutics obtient la désignation de maladie pédiatrique rare de la FDA pour le RLF-TD011 FDA THÉRAPEUTIQUE DE SECOURS RLF-TD011 Epidermolyse Bulleuse Maladie Pédiatrique Rare
PRESS RELEASE published on 05/22/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 Relief Therapeutics granted FDA Rare Pediatric Disease Designation for RLF-TD011 in treating epidermolysis bullosa, a rare genetic skin disorder. Potent antimicrobial & anti-inflammatory activity shown FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease Designation
BRIEF published on 05/15/2025 at 07:05, 1 year 1 month ago Relief Therapeutics Announces 2025 AGM Agenda Annual General Meeting Financial Statements Shareholder Voting Board Re-election Compensation Approval
BRIEF published on 05/15/2025 at 07:05, 1 year 1 month ago Relief Therapeutics annonce l'ordre du jour de l'assemblée générale annuelle 2025 États Financiers Assemblée Générale Annuelle Réélection Du Conseil D'administration Vote Des Actionnaires Approbation De L'indemnisation
Published on 07/09/2026 at 14:00, 36 minutes ago GameSquare Signs Dairy MAX as Brand Partner for the World of Dance
Published on 07/09/2026 at 14:00, 36 minutes ago Horizon Aircraft Selects BETA Technologies Advanced Flight Control Computers and Software for the Cavorite X7
Published on 07/09/2026 at 14:00, 36 minutes ago Loop Industries Announces Date for First Quarter Fiscal 2027 Financial Results and Conference Call
Published on 07/09/2026 at 14:05, 30 minutes ago DJI Puts Drones to the Test on the World's Highest Peak, Advancing Critical High-Altitude Delivery, Mapping, and Climate Research Applications
Published on 07/09/2026 at 12:35, 2 hours ago Cognizant to scale to 5,000 Frontier Certified Engineers and 10,000 Frontier Business Operators
Published on 07/09/2026 at 12:30, 2 hours 6 minutes ago Immunic to Participate in Investor Conferences in July
Published on 07/09/2026 at 12:16, 2 hours 19 minutes ago Phase III GRAPPA trial supports ATLG (Grafalon®) as standard of care in matched unrelated donor stem cell transplantation
Published on 07/09/2026 at 13:56, 39 minutes ago Statement of transactions in own shares from July 6, 2026 to July 8, 2026
Published on 07/09/2026 at 13:56, 39 minutes ago Déclaration des transactions sur actions propres réalisées du 06/07/2026 au 08/07/2026
Published on 07/09/2026 at 07:30, 7 hours 6 minutes ago Half-year liquidity contract statement June 30, 2026
Published on 07/09/2026 at 07:30, 7 hours 6 minutes ago Half-year liquidity contract statement June 30, 2026
